Xencor, Inc. (NASDAQ:XNCR – Get Free Report) has been assigned an average rating of “Buy” from the eight ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $35.38.
Several brokerages have commented on XNCR. BTIG Research decreased their target price on shares of Xencor from $56.00 to $38.00 and set a “buy” rating for the company in a report on Tuesday, April 16th. Royal Bank of Canada lowered their price objective on shares of Xencor from $32.00 to $31.00 and set an “outperform” rating on the stock in a research report on Friday, June 14th. Wedbush restated an “outperform” rating and issued a $34.00 target price (down previously from $36.00) on shares of Xencor in a report on Thursday, June 13th. StockNews.com raised Xencor from a “sell” rating to a “hold” rating in a research report on Saturday, March 9th. Finally, BMO Capital Markets dropped their price target on Xencor from $34.00 to $32.00 and set an “outperform” rating on the stock in a research report on Friday, June 14th.
Read Our Latest Research Report on XNCR
Institutional Inflows and Outflows
Xencor Price Performance
NASDAQ XNCR opened at $18.93 on Friday. The stock has a market capitalization of $1.17 billion, a P/E ratio of -8.64 and a beta of 0.82. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.08 and a current ratio of 7.08. The business’s fifty day moving average is $21.77 and its two-hundred day moving average is $21.50. Xencor has a 1 year low of $16.49 and a 1 year high of $26.84.
Xencor (NASDAQ:XNCR – Get Free Report) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.28). The company had revenue of $12.80 million for the quarter, compared to analysts’ expectations of $23.07 million. Xencor had a negative net margin of 82.23% and a negative return on equity of 20.29%. The company’s revenue for the quarter was down 32.3% on a year-over-year basis. During the same period in the prior year, the company earned ($1.02) earnings per share. On average, research analysts forecast that Xencor will post -3.5 earnings per share for the current fiscal year.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
See Also
- Five stocks we like better than Xencor
- Basic Materials Stocks Investing
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Stock Splits, Do They Really Impact Investors?
- MarketBeat Week in Review – 6/24 – 6/28
- What is the Nikkei 225 index?
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.